compounded semaglutide fda news US proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs FDA restricts non-approved compounded GLP-1

Protein requirements increase in importance during this phase

Medications such as tirzepatide (Mounjaro and Zepbound ) act on both GLP-1 and GIP, which is why theyre called dual agonists

If your patients are wondering if one of these drugs might be a fit, you can recommend they consult a healthcare provider

Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) Retatrutide (LY3437943) is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist in Phase III clinical trials